Form 4: Acrivon Therapeutics COO Sells Shares to Cover Tax Obligations

Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, sold 613 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, sold 613 shares of common stock on November 14, 2024.
• The sale was executed at a price of $7.92 per share.
• This transaction was to cover mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following the transaction, Mr. Devroe beneficially owns 67,871 shares of Acrivon Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is a standard disclosure related to tax obligations on vested stock.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, as mandated by the SEC.
• The sale of shares to cover tax obligations is a common occurrence among executives who receive stock-based compensation.
• Similar filings can be seen across the biotechnology industry, where stock options and restricted stock units are frequently used as part of compensation packages.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Acrivon Therapeutics, insider trading, Form 4, stock sale, Eric Devroe, tax withholding, restricted stock units